Ipratropium bromide and Perforomist drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ipratropium bromide (ipratropium bromide) and Perforomist (formoterol fumarate). Common drug interactions include insomnia among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Ipratropium bromide and Perforomist. It is created by eHealthMe based on reports of 60 people who take the same drugs from the FDA, and is updated regularly.

What is Ipratropium bromide?

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 17,965 Ipratropium bromide users. Check the latest studies of Ipratropium bromide.

What is Perforomist?

Perforomist has active ingredients of formoterol fumarate. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 1,431 Perforomist users. Check the latest studies of Perforomist.



On Jul, 28, 2026

60 people who take Ipratropium bromide and Perforomist together, and have interactions are studied.

Ipratropium bromide and Perforomist drug interactions.

What are the common drug interactions of Ipratropium Bromide and Perforomist, by gender? *:

female:

  1. Insomnia (sleeplessness)
  2. Intestinal obstruction
  3. Local swelling (swelling at the site of some application of substance or injury)
  4. Lower respiratory tract infection
  5. Lung disorder (lung disease)
  6. Memory impairment
  7. Multiple allergies (allergy to multiple agents)
  8. Nasal discomfort
  9. Oral candidiasis (fungal infection of mouth)
  10. Oral pain

male:

  1. Dyspnoea (difficult or laboured respiration)
  2. Cough
  3. Psoriasis (immune-mediated disease that affects the skin)
  4. Seasonal allergy (allergic condition due to certain season)
  5. Sneezing
  6. Arthralgia (joint pain)
  7. Asthenia (weakness)
  8. Bacterial infection
  9. Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
  10. Depression

What are the common drug interactions of Ipratropium Bromide and Perforomist, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi)
  2. Hypoxia (low oxygen in tissues)

10-19:

  1. Hypovolaemic shock (shock caused by severe blood or fluid loss)
  2. Tracheal haemorrhage (bleeding from trachea)

20-29:

  1. Implant site erosion
  2. Pneumonia

30-39:

n/a

40-49:

  1. Aphasia (damage to the parts of the brain that control language)
  2. Drug ineffective
  3. Dysphonia (speech disorder attributable to a disorder of phonation)
  4. Oral candidiasis (fungal infection of mouth)
  5. Oral pain

50-59:

n/a

60+:

  1. Dyspnoea (difficult or laboured respiration)
  2. Cough
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Nausea (feeling of having an urge to vomit)
  5. Oesophagitis (inflammation of oesophagus)
  6. Pulmonary embolism (blockage of the main artery of the lung)
  7. Pulmonary eosinophilia (increase in the number of eosinophiles in the blood causeing lung infection)
  8. Respiratory disorder (respiratory disease)
  9. Respiratory distress (difficulty in breathing)
  10. Tongue ulceration (ulcers on tongue)

What are the existing conditions these people have? *

  1. Immunodeficiency Common Variable: 13 people, 21.67%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 10 people, 16.67%
  3. Neuropathy Peripheral (surface nerve damage): 6 people, 10.00%
  4. Fluid Retention (an abnormal accumulation of fluid in the blood): 5 people, 8.33%
  5. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 6.67%
  6. High Blood Pressure: 4 people, 6.67%
  7. Depression: 4 people, 6.67%
  8. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 3 people, 5.00%
  9. Psoriasis (immune-mediated disease that affects the skin): 3 people, 5.00%
  10. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ipratropium bromide and Perforomist?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ipratropium bromide and Perforomist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ipratropium bromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Perforomist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ipratropium bromide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Perforomist and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ipratropium bromide and formoterol fumarate (the active ingredients of Ipratropium bromide and Perforomist, respectively), and Ipratropium bromide and Perforomist (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: